145 related articles for article (PubMed ID: 38109113)
1. Local Treatment and Treatment-Related Adverse Effects Among Patients With Advanced Prostate Cancer.
Khan S; Chang SH; Wang M; Kim EH; Schoen MW; Rocuskie-Marker C; Drake BF
JAMA Netw Open; 2023 Dec; 6(12):e2348057. PubMed ID: 38109113
[TBL] [Abstract][Full Text] [Related]
2. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
[TBL] [Abstract][Full Text] [Related]
4. Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer.
Wallis CJD; Zhao Z; Huang LC; Penson DF; Koyama T; Kaplan SH; Greenfield S; Luckenbaugh AN; Klaassen Z; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Hoffman KE; Barocas DA
JAMA Oncol; 2022 Jan; 8(1):50-59. PubMed ID: 34792527
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
6. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study.
Mazariego CG; Egger S; King MT; Juraskova I; Woo H; Berry M; Armstrong BK; Smith DP
BMJ; 2020 Oct; 371():m3503. PubMed ID: 33028540
[TBL] [Abstract][Full Text] [Related]
7. Definitive treatment and risk of death among men diagnosed with metastatic prostate cancer at the Veterans Health Administration.
Drake BF; Khan S; Wang M; Hicks V; Nichols K; Taylor M; Kim EH; Chang SH
Ann Epidemiol; 2023 Mar; 79():24-31. PubMed ID: 36640917
[TBL] [Abstract][Full Text] [Related]
8. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.
Chen RC; Basak R; Meyer AM; Kuo TM; Carpenter WR; Agans RP; Broughman JR; Reeve BB; Nielsen ME; Usinger DS; Spearman KC; Walden S; Kaleel D; Anderson M; Stürmer T; Godley PA
JAMA; 2017 Mar; 317(11):1141-1150. PubMed ID: 28324092
[TBL] [Abstract][Full Text] [Related]
9. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Acute and Chronic Surgical Complications Following Robot-Assisted, Laparoscopic, and Traditional Open Radical Prostatectomy Among Men in Taiwan.
Wu SY; Chang CL; Chen CI; Huang CC
JAMA Netw Open; 2021 Aug; 4(8):e2120156. PubMed ID: 34432012
[TBL] [Abstract][Full Text] [Related]
11. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.
Hampson LA; Cowan JE; Zhao S; Carroll PR; Cooperberg MR
Eur Urol; 2015 Sep; 68(3):480-6. PubMed ID: 25656807
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.
Nguyen PL; Chen MH; Hoffman KE; Chen RC; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV
BJU Int; 2012 Jul; 110(2):201-5. PubMed ID: 22085233
[TBL] [Abstract][Full Text] [Related]
15. Use of advanced treatment technologies among men at low risk of dying from prostate cancer.
Jacobs BL; Zhang Y; Schroeck FR; Skolarus TA; Wei JT; Montie JE; Gilbert SM; Strope SA; Dunn RL; Miller DC; Hollenbeck BK
JAMA; 2013 Jun; 309(24):2587-95. PubMed ID: 23800935
[TBL] [Abstract][Full Text] [Related]
16. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.
Stanford JL; Feng Z; Hamilton AS; Gilliland FD; Stephenson RA; Eley JW; Albertsen PC; Harlan LC; Potosky AL
JAMA; 2000 Jan; 283(3):354-60. PubMed ID: 10647798
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.
Kishan AU; Karnes RJ; Romero T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Braccioforte M; Huland H; Tran PT; Martin S; Martínez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Chang AJ; Pisansky TM; Choo R; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; D'Amico AV; Rettig MB; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D
JAMA Netw Open; 2021 Jul; 4(7):e2115312. PubMed ID: 34196715
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
